Evidence map›Paper›PMID 40626705›Full record

ArticleJournal of virology2025

Differential decreases in various HIV DNA regions and HIV transcripts after ART initiation during chronic infection.

Julie Janssens, Cordelia Isbell, Sun Jin Kim, Adam Wedrychowski, Alton Barbehenn, Rebecca Hoh, Satish K Pillai, Michael J Peluso, Sulggi A Lee, Timothy J Henrich and 3 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julie JanssensDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Cordelia IsbellDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Sun Jin KimDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Adam WedrychowskiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Alton BarbehennDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Rebecca HohDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Satish K PillaiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Michael J PelusoDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Sulggi A LeeDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Timothy J HenrichDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Nadia R RoanDepartment of Urology, University of California, San Francisco (UCSF), San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Steven A YuklDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0002-4578-9872

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Understanding and targeting the HIV-expressing reservoir to reduce immune activationR01AI183666 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Steven A Yukl · 2024 to 2026
$2.4M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
A pharmacogenomics study of HIV latency: the role of PD-1 signalingK23GM112526 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2014 to 2018
$908k
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
Gates Foundation INV-002703NIAID NIH HHS K24 AI174971NIAID NIH HHS P01 AI169606NIAID NIH HHS R01 AI132128NIAID NIH HHS R01 AI183666NIAID NIH HHS UM1 AI164560NIDDK NIH HHS R01 DK120387NIGMS NIH HHS K23 GM112526
6 · The paper itself

Abstract

HIV-transcribing cells persist on ART and likely contribute to inflammation as well as the viral rebound that occurs after stopping ART. However, it is unclear how ART start time and prolonged time on ART affect the clearance of cells expressing HIV transcripts that differ in their processivity and/or the presence of mutations. To investigate these questions, we measured levels of various HIV transcripts and their corresponding HIV DNA regions in longitudinal samples of peripheral CD4+ T cells obtained from 10 individuals during untreated chronic infection (T1) and up to four additional timepoints on suppressive ART (median years after ART start: T2 = 0.9; T3 = 2.9; T4 = 5.2; T5 = 7). Before ART, the pattern of HIV transcripts suggested blocks to elongation and completion, and only ~1% of intact proviruses were transcribing intact HIV RNA. After ART, we observed decreases in most HIV transcripts. Multiply spliced HIV RNA tended to decrease faster than initiated HIV RNA, and intact HIV RNA decreased faster than 5' defective HIV RNA. ART reduced completed but not elongated or Pol HIV RNA as normalized to HIV DNA. While most proviruses and HIV transcripts showed no further decline after T2, multiply spliced HIV RNA continued to decline through T3, and R-U5-pre-Gag HIV DNA continued to decline through T4, suggesting their clearance may be dictated by different or more sustained immune mechanisms. No further changes were observed after T4. These findings suggest the need for new therapies that can target the remaining proviruses/transcripts and/or modulate the expression of completed, multiply spliced, and intact HIV RNA.IMPORTANCEEven in ART-treated people living with HIV (PWH), expression of different viral products may contribute to immune activation, inflammation, organ damage, and reduced life expectancy. We quantified different types of HIV DNA and transcripts in people living with untreated chronic HIV and up to 4 timepoints over 6-10 years on ART. During the first year on ART, multiply spliced HIV RNA decreased faster than total HIV RNA, and intact HIV RNA decreased faster than defective RNA. Multiply spliced HIV RNA continued to decline over 1-3 years on ART, and proviruses containing the 5' end declined over years 3-5, suggesting differences in the immune clearance of various HIV transcripts and proviruses. While intact HIV RNA became undetectable, levels of incomplete or defective HIV transcripts reached an equilibrium after 3 years on ART, indicating the limits of the immune system and ART to reduce incomplete/defective HIV transcripts that may still contribute to immune activation.

Indexed as

Anti-HIV AgentsDNA, ViralHIV-1HIV InfectionsRNA, ViralAdultCD4-Positive T-LymphocytesChronic DiseaseFemaleHumansLongitudinal StudiesMaleMiddle AgedPersistent InfectionProvirusesTranscription, GeneticAnti-HIV AgentsDNA, ViralRNA, ViralARTDNAHIVHIV-1RNAtranscription

Identifiers

PMID40626705
PMCPMC12363177

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.